Glassman Wealth Services’s Agios Pharmaceuticals AGIO Stock Holding History

Glassman Wealth Services’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	-$2.23K	–	249
2023 Q4	$2.23K	Hold	100	–	–	﹤0.01%	1323
2023 Q3	$2.48K	Hold	100	–	–	﹤0.01%	1268
2023 Q2	$2.83K	Hold	100	–	–	﹤0.01%	1156
2023 Q1	$2.3K	Hold	100	–	–	﹤0.01%	1198
2022 Q4	$2.81K	Hold	100	–	–	﹤0.01%	1179
2022 Q3	$3K	Hold	100	–	–	﹤0.01%	1095
2022 Q2	$2K	Hold	100	–	–	﹤0.01%	1192
2022 Q1	$3K	Buy	+100	New	+$3.06K	﹤0.01%	1094
2021 Q3	–	Sell	-76	Closed	-$4K	–	1566
2021 Q2	$4K	Buy	+76	New	+$4.25K	﹤0.01%	960
2020 Q3	–	Sell	-49	Closed	-$3K	–	1308
2020 Q2	$3K	Buy	+49	New	+$2.27K	﹤0.01%	720
2020 Q1	–	Sell	-14	Closed	-$1K	–	1096
2019 Q4	$1K	Buy	14 +7	+100%	+$265	﹤0.01%	837
2019 Q3	$0	Sell	7 -21	-75%	-$869	﹤0.01%	1022
2019 Q2	$1K	Buy	28 +19	+211%	+$1.01K	﹤0.01%	786
2019 Q1	$1K	Buy	+9	New	+$524	﹤0.01%	749

Other funds holding AGIO

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Glassman Wealth Services's AGIO Position: Q1 2024 in Review

Glassman Wealth Services sold out of Agios Pharmaceuticals (AGIO) in Q1 2024, closing a stake of 100 shares — an estimated $2.23K sold.

Glassman Wealth Services first reported a position in AGIO in Q1 2019 and held it in 14 quarters. The position peaked at $4K in Q2 2021. 186 funds tracked by Wall St. Rank hold AGIO as of Q1 2024.

Glassman Wealth Services reported no remaining Agios Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Glassman Wealth Services sold 100 Agios Pharmaceuticals shares in Q1 2024, an estimated $2.23K.
Glassman Wealth Services first reported a position in Agios Pharmaceuticals in Q1 2019 and held it in 14 quarters.
Glassman Wealth Services's Agios Pharmaceuticals position peaked at $4K in Q2 2021.
186 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.